TH.TO - Theratechnologies Inc.

Toronto - Toronto Delayed Price. Currency in CAD
2.8900
-0.2000 (-6.47%)
As of 4:00PM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close3.0900
Open2.9800
Bid2.8300 x 0
Ask2.8300 x 0
Day's Range2.8100 - 3.0100
52 Week Range1.9300 - 7.9800
Volume199,307
Avg. Volume146,467
Market Cap222.439M
Beta (5Y Monthly)1.51
PE Ratio (TTM)N/A
EPS (TTM)-0.2050
Earnings DateApr 14, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.37
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers

      Theratechnologies Inc. (Theratechnologies) (TH.TO) (THTX), a commercial-stage biopharmaceutical company, today announced new positive results for its investigational Sortilin (SORT1) targeting peptide-drug conjugates (PDCs) which will be presented in three posters during AACR’s virtual annual meeting II on June 22, 2020. The strong activity of our technology against various cancers is very promising.

    • GlobeNewswire

      Theratechnologies to Present at the RBC Capital Markets Global Healthcare Conference on May 19, 2020

      MONTREAL, May 12, 2020 -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that management.

    • GlobeNewswire

      Theratechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Theratechnologies Inc., or Theratechnologies (TH.TO) (THTX), a commercial-stage biopharmaceutical company, announced today that Paul Lévesque, the current President and Chief Executive Officer of Theratechnologies, was granted 487,421 stock options, or Options, to purchase an aggregate of 487,421 common shares of Theratechnologies under Nasdaq Listing Rule 5635(c)(4). The grant was made outside of Theratechnologies’ existing share option plan, or Plan, in connection with Mr. Lévesque’s previously-announced employment by Theratechnologies as its President and Chief Executive Officer.

    • Thomson Reuters StreetEvents

      Edited Transcript of TH.TO earnings conference call or presentation 14-Apr-20 12:30pm GMT

      Q1 2020 Theratechnologies Inc Earnings Call

    • GlobeNewswire

      Theratechnologies Announces Financial Results for the First Quarter of 2020

      Theratechnologies Inc. (Theratechnologies) (TH.TO) (THTX), a commercial-stage biopharmaceutical company, today announced its financial results for the first quarter ended February 29, 2020. Financial results presented in this press release are taken from the Company’s Management's Discussion and Analysis, or MD&A, and unaudited consolidated financial statements for the three-month period ended February 29, 2020, which have been prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB.

    • Thomson Reuters StreetEvents

      Edited Transcript of TH.TO earnings conference call or presentation 25-Feb-20 1:30pm GMT

      Q4 2019 Theratechnologies Inc Earnings Call

    • GlobeNewswire

      THERATECHNOLOGIES PROVIDES BUSINESS UPDATE RELATED TO CURRENT COVID-19 SITUATION

      Theratechnologies Inc. (Theratechnologies) (TH.TO) (THTX), a commercial-stage biopharmaceutical company, today issued an update on the Company’s activities in relation to the current worldwide COVID-19 pandemic. “Theratechnologies’ focus amidst the COVID-19 pandemic has been to ensure that current and future patients have access to our medicines while we also prioritize the health and safety of our employees worldwide,” said Luc Tanguay, President and CEO, Theratechnologies. Theratechnologies quickly implemented measures to alleviate the impact of the COVID-19 situation on patients and staff.

    • GlobeNewswire

      Visceral Fat is a Predictor of Liver Fibrosis and Fibrosis Progression in People Living With HIV

      Theratechnologies Inc. (Theratechnologies) (TH.TO) (THTX), a commercial-stage biopharmaceutical company, is pleased to announce that Dr. Lindsay Fourman, from Harvard Medical School, presented data demonstrating that visceral fat is a clinical predictor of liver fibrosis and liver fibrosis progression in an oral presentation during CROI 2020. This information may further inform the field as to the development of prediction tools and therapeutic strategies for hepatic fibrosis in this population.

    • Change to Theratechnologies Management
      PR Newswire

      Change to Theratechnologies Management

      The board of directors of Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) is pleased to announce the appointment of Paul Lévesque as the company's President and CEO, effective April 6, 2020, replacing Luc Tanguay, who is retiring after a 23-year career. Mr. Tanguay will remain available to ensure a smooth transition.

    • Introducing Theratechnologies (TSE:TH), The Stock That Soared 334% In The Last Five Years
      Simply Wall St.

      Introducing Theratechnologies (TSE:TH), The Stock That Soared 334% In The Last Five Years

      Theratechnologies Inc. (TSE:TH) shareholders might be concerned after seeing the share price drop 22% in the last...

    • GlobeNewswire

      Theratechnologies Announces Financial Results for Fiscal Year 2019

      Theratechnologies Inc. (Theratechnologies) (TH.TO) (THTX), a commercial-stage biopharmaceutical company, today announced its financial results for the year ended November 30, 2019. The financial results presented in this press release are taken from the Company’s Management's Discussion and Analysis, or MD&A, and audited consolidated financial statements for the twelve-month period ended November 30, 2019, which have been prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB.

    • GlobeNewswire

      Theratechnologies Signs Agreements With Massachusetts General Hospital and Dr. Steven Grinspoon

      Theratechnologies Inc. (Theratechnologies) (TH.TO) (THTX), a commercial-stage biopharmaceutical company, is pleased to announce the signing of long-term agreements with the Massachusetts General Hospital (MGH) and Dr. Steven Grinspoon towards the development of tesamorelin for the potential treatment  of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in people living with HIV (Study).

    • GlobeNewswire

      Theratechnologies Issues Preliminary Revenue Estimates for Fiscal Year 2019 and Revenue Guidance for Fiscal Year 2020

      Theratechnologies Inc. (Theratechnologies) (TH.TO) (THTX), a commercial-stage biopharmaceutical company, today provided preliminary revenue estimates for its recently completed fiscal year 2019 and revenue guidance for fiscal year 2020. Theratechnologies expects to report consolidated revenues of approximately US$63.3 million for fiscal year 2019 compared to US$45.2 million for the previous year, representing an increase of approximately 40%. Consolidated revenues of approximately US$16.5 million for the fourth quarter of 2019 represent an increase of 17.7% compared to Q4 of 2018, and 2.1% compared to Q3 2019.

    • GlobeNewswire

      Theratechnologies’ Oncology Platform Improves Efficacy and Tolerability of Docetaxel in Vivo and in Vitro

      Theratechnologies Inc. (Theratechnologies) (TH.TO) (THTX), a commercial-stage biopharmaceutical company, is pleased to report on new data presented today at the San Antonio Breast Cancer Symposium (SABCS). Results from in vitro and in vivo experiments demonstrated that TH-1902 (docetaxel conjugated to Theratechnologies’ novel investigational peptide TH19P01), currently being developed for the treatment of triple-negative breast cancer (TNBC), improves efficacy and tolerability compared to docetaxel alone.

    • GlobeNewswire

      Theratechnologies’ CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City

      Theratechnologies Inc. (Theratechnologies) (TH.TO) is pleased to announce that Philippe Dubuc, Senior Vice President and Chief Financial Officer will attend the 31st Annual Healthcare Conference starting at 12:30 p.m. on December 3rd, 2019 at the Lotte New York Palace in New York City. Mr. Dubuc will hold several meetings with representatives from various investment firms to discuss the latest developments announced by the Company including the approval of Trogarzo® in Europe by the European Commission and the publication of clinical trial results in the Lancet HIV on the effects of tesamorelin on Non-alcoholic Fatty Liver Disease (NAFLD) in people living with HIV.

    • GlobeNewswire

      Theratechnologies Starts Commercialization of New EGRIFTA SVᵀᴹ in the United States

      Theratechnologies Inc. (Theratechnologies) (TH.TO) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, is pleased to announce that EGRIFTA SVᵀᴹ (2mg/vial) is now commercially available in the United States.

    • GlobeNewswire

      Theratechnologies’ CFO to Attend Stifel Healthcare Conference in New York City

      Theratechnologies Inc. (Theratechnologies) (TH.TO), a commercial-stage biopharmaceutical company, is pleased to announce that Philippe Dubuc, Senior Vice President and Chief Financial Officer, will attend the Stifel Healthcare Conference which will be held in New York City on November 19th, 2019. Mr. Dubuc will hold several meetings with representatives from various investment firms to discuss the latest developments announced by the Company including the approval of Trogarzo® in Europe by the European Commission and the publication of clinical trial results in the Lancet HIV on the effects of tesamorelin on Non-alcoholic Fatty Liver Disease (NAFLD) in people living with HIV.

    • GlobeNewswire

      Theratechnologies Provides Details About R&D Day Webcast

      Theratechnologies (TH.TO) is a commercial-stage pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.

    • Does Theratechnologies Inc.'s (TSE:TH) CEO Salary Compare Well With Others?
      Simply Wall St.

      Does Theratechnologies Inc.'s (TSE:TH) CEO Salary Compare Well With Others?

      Luc Tanguay has been the CEO of Theratechnologies Inc. (TSE:TH) since 2012. First, this article will compare CEO...

    • GlobeNewswire

      REMINDER - Tesamorelin Study Results on NAFLD Published in Lancet HIV

      Theratechnologies Inc. (Theratechnologies) (TH.TO) (NASDAQ:THTX) is pleased to announce that results from a recent trial conducted at the Massachusetts General Hospital and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health on the effects of tesamorelin on Non-alcoholic Fatty Liver Disease (NAFLD) in HIV were published today in the Lancet HIV. NAFLD is a substantial cause of liver-related morbidity in people living with HIV and is a precursor of Non-alcoholic steatohepatitis (NASH). The randomized, double-blind, multicenter trial assessed the effect of tesamorelin on liver fat and histology in people living with HIV with NAFLD.

    • GlobeNewswire

      Tesamorelin Study Results on NAFLD Published in Lancet HIV

      Theratechnologies Inc. (Theratechnologies) (TH.TO) (NASDAQ:THTX) is pleased to announce that results from a recent trial conducted at the Massachusetts General Hospital and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health on the effects of tesamorelin on Non-alcoholic Fatty Liver Disease (NAFLD) in HIV were published today in the Lancet HIV. NAFLD is a substantial cause of liver-related morbidity in people living with HIV and is a precursor of Non-alcoholic steatohepatitis (NASH). The randomized, double-blind, multicenter trial assessed the effect of tesamorelin on liver fat and histology in people living with HIV with NAFLD.

    • Thomson Reuters StreetEvents

      Edited Transcript of TH.TO earnings conference call or presentation 8-Oct-19 12:30pm GMT

      Q3 2019 Theratechnologies Inc Earnings Call

    • GlobeNewswire

      Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing 

      “Theratechnologies’ NASDAQ listing is yet another step forward for our Company with growing sales from two commercialized products and a strong pipeline. Over the last five years, we have reached significant milestones and our progress continues.

    • GlobeNewswire

      Theratechnologies Announces Financial Results for the Third Quarter of 2019

      Theratechnologies Inc. (Theratechnologies) (TH.TO) today announced its financial results for the third quarter ended August 31, 2019. The coming days and weeks will be no exception with the expected listing of our common shares on NASDAQ and the anticipated commercial launch of EGRIFTA SVTM in the United States,” said Luc Tanguay, President and CEO, Theratechnologies Inc.

    • GlobeNewswire

      1.7 Million Dollars Grant Towards Development of Theratechnologies’ Targeted Oncology

      Theratechnologies Inc. (Theratechnologies) (TH.TO) is pleased to announce that the Canadian Cancer Society and the Government of Quebec, through the Consortium Québécois sur la découverte du médicament (CQDM), will contribute to a grant totaling 1.7 million dollars to l’Université du Québec à Montréal (UQAM) as part of the overall investment made by Theratechnologies towards the development of its targeted oncology platform. The funds have been earmarked for work conducted by Dr Borhane Annabi at the Molecular Oncology Laboratory of the UQAM. Dr Annabi and his team will focus their efforts on the development of the targeted oncology platform in triple-negative breast cancer.